Peptides Research Hub

Clinical Trial Identifier

NCT02692716

Oral semaglutide (with SNAC absorption enhancer), part of the PIONEER program.

Trial details

Identifier
NCT02692716
Sponsor
Novo Nordisk
Asset
Oral semaglutide (with SNAC absorption enhancer)
Program
PIONEER
Phase
Phase III
Therapeutic area
Type 2 Diabetes

Program context

PIONEER

HbA1c reductions of approximately 0.8 to 1.4 percentage points at the 14 mg dose across the program; weight reductions of 2 to 4 kg. PIONEER-6 demonstrated cardiovascular non-inferiority versus placebo in a high-risk T2DM population. Efficacy is somewhat attenuated compared with the subcutaneous form due to bioavailability constraints inherent to oral delivery.

Read the PIONEER spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.